Protocol design backed by the full landscape
Clinical trial landscape research takes 3–6 months of analyst time. Screen failure rates remain high because eligibility criteria are not systematically matched to real patient profiles. Skippy Trial Design gives you the full landscape in a single API call — endpoints, sponsors, precedents, and patient match.
What Trial Design does
Disease trial landscape analysis
Surveys all active trials for an indication — phases, sponsors, endpoints, drug classes — synthesized from 578,000+ registered studies. Know what's running, who's running it, and what endpoints the field is using.
Endpoint benchmarking
Compares primary and secondary endpoints across trials in the same indication with evidence-based precedent matching. Identify which endpoints have FDA precedent and which carry regulatory risk.
Protocol design validation
Validates a proposed design — drug, phase, endpoint, patient population — against clinical guideline precedents and CPIC gene-based eligibility criteria before a single patient is screened.
Patient-trial matching
Matches a patient profile — diagnosis, biomarkers, prior treatments, age — to eligible trials, with evidence-grounded eligibility evaluation and expanded access / compassionate use identification.
Pharma, CROs, and academic centers
Evidence traced to NCT identifiers
All trial data is traceable to ClinicalTrials.gov NCT identifiers. Protocol design checks reference CPIC pharmacogenomics guidelines for genotype-based eligibility criteria. ClinVar variant-disease associations integrated for biomarker-guided eligibility matching.
Expanded access and compassionate use programs included in patient-trial matching. Every landscape analysis generates an audit record with a versioned evidence snapshot.
See Trial Design in your clinical operations workflow
We work with pharma, CROs, and academic medical centers. Let's talk about your trial design and patient matching problem.